Bluejay Diagnostics shares surge 19.37% after-hours after enrolling 545 patients in SYMON II study, exceeding enrollment targets and advancing commercial readiness.

Bluejay Diagnostics surged 19.37% in after-hours trading following the announcement that it enrolled 545 patients in its SYMON II multicenter IL-6 monitoring study, surpassing its 750-patient target. The enrollment, conducted under approved IRB protocols, reduces clinical execution risk and advances manufacturing readiness for U.S. commercial production. The company also reported completing cartridge characterization and producing antibodies for over 10 million test cartridges, addressing supply capacity and commercialization timelines. These developments, coupled with ongoing FDA submission preparations, underscore significant progress in its pipeline and scalability, positioning the stock for a strong after-hours rally.